Considering the potent roles of p53 in both tumor suppression and aging, in the course of developing p53-targeting drugs, one important balance to maintain is to activate wtp53-dependent tumor suppression without inducing p53-dependent aging. The gene discussed is TP53; the disease is neoplasm.